Show simple item record

dc.contributor.authorManegold, C
dc.contributor.authorThatcher, Nick
dc.date.accessioned2010-07-22T09:46:54Z
dc.date.available2010-07-22T09:46:54Z
dc.date.issued2007-08
dc.identifier.citationSurvival improvement in thoracic cancer: progress from the last decade and beyond. 2007, 57 Suppl 2:S3-5 Lung Canceren
dc.identifier.issn0169-5002
dc.identifier.pmid17686443
dc.identifier.doi10.1016/S0169-5002(07)70420-8
dc.identifier.urihttp://hdl.handle.net/10541/108148
dc.description.abstractLung cancer remains a major concern, being the most common cancer worldwide, and with the incidence continuing to increase in many countries. Survival following diagnosis of non-small cell lung cancer (NSCLC) remains relatively low, with 1-year overall survival being approximately 25%. However, the development of new drugs and innovative treatment approaches is improving the outlook for patients with NSCLC. Important contributions have been made to the treatment of NSCLC and continue to do so with the development of gemcitabine, and more recently, pemetrexed. Major advances in the understanding of cancer biology have identified many potential targets for rationally designed novel therapies. Many of these targets are components of signalling pathways or metabolic processes that contribute to one of the hallmarks of the cancer phenotype. The novel targeted therapy enzastaurin, which is a derivative of the prototypical protein kinase C inhibitor staurosporine, is currently being investigated as monotherapy in NSCLC following first- or second-line chemotherapy. Research into the use of pharmacogenomics to tailor therapy to the individual patient is another innovative field that is yielding promising results that may help to improve the clinical outcome for patients with NSCLC in the future.
dc.language.isoenen
dc.subject.meshCarcinoma, Non-Small-Cell Lung
dc.subject.meshHumans
dc.subject.meshLung Neoplasms
dc.subject.meshPharmacogenetics
dc.titleSurvival improvement in thoracic cancer: progress from the last decade and beyond.en
dc.typeArticleen
dc.contributor.departmentHeidelberg University, Interdisciplinary Thoracic Oncology and Department of Surgery, University Medical Center Mannheim, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Germany. christian.manegold@chir.ma.uni-heidelberg.deen
dc.identifier.journalLung Canceren
html.description.abstractLung cancer remains a major concern, being the most common cancer worldwide, and with the incidence continuing to increase in many countries. Survival following diagnosis of non-small cell lung cancer (NSCLC) remains relatively low, with 1-year overall survival being approximately 25%. However, the development of new drugs and innovative treatment approaches is improving the outlook for patients with NSCLC. Important contributions have been made to the treatment of NSCLC and continue to do so with the development of gemcitabine, and more recently, pemetrexed. Major advances in the understanding of cancer biology have identified many potential targets for rationally designed novel therapies. Many of these targets are components of signalling pathways or metabolic processes that contribute to one of the hallmarks of the cancer phenotype. The novel targeted therapy enzastaurin, which is a derivative of the prototypical protein kinase C inhibitor staurosporine, is currently being investigated as monotherapy in NSCLC following first- or second-line chemotherapy. Research into the use of pharmacogenomics to tailor therapy to the individual patient is another innovative field that is yielding promising results that may help to improve the clinical outcome for patients with NSCLC in the future.


Files in this item

This item appears in the following Collection(s)

Show simple item record